Integra LifeSciences Holdings Stock Performance Snapshot

Integra LifeSciences Holdings (IART) has attracted fresh attention after recent share price moves, with the stock last closing at $19.79 and showing varied returns over the past month and past 3 months.

For investors tracking medium term trends, Integra LifeSciences Holdings shows a return of 5.5% over the past month and a very strong 85.1% gain over the past 3 months, set against a longer 3 year total return decline of 56.5%.

At a share price of $19.79, Integra LifeSciences Holdings has seen strong short term momentum, with an 85.1% 90 day share price return contrasting with a weaker 3 year total shareholder return, which is down 56.5%.

If you are weighing Integra LifeSciences Holdings against other opportunities in healthcare, it can help to widen the lens and scan 40 healthcare AI stocks

Integra LifeSciences Holdings runs a broad surgical and wound care business, yet the stock’s sharp 90 day rebound sits against multi year value erosion. Is the market now paying a fair price for what you get?

Most Popular Narrative: 26.7% Undervalued

Integra LifeSciences Holdings last closed at $19.79, while the most widely followed valuation narrative points to a fair value of $27, implying a sizeable gap that investors are watching closely.

With the global population aging and chronic disease prevalence increasing, Integra's leadership in advanced wound care and tissue technology positions it to benefit disproportionately from sustained volume growth and pricing power, fueling robust multi-year revenue and market share gains.

Want to see what kind of revenue path and margin rebuild would support that $27 fair value for Integra LifeSciences Holdings? The narrative leans on ambitious earnings recovery and a future profit multiple more often associated with higher growth medical device stocks. Curious which specific profit and cash flow assumptions sit under that price tag and how long the turnaround runway runs?

Result: Fair Value of $27 (UNDERVALUED)

However, Integra LifeSciences Holdings still faces meaningful risks, including ongoing regulatory and recall issues and pressure on pricing that could limit margins and undermine the bullish fair value case.

Next Steps

Mixed signals around Integra LifeSciences Holdings can be hard to interpret, so it makes sense to review the details yourself and decide quickly. For a clearer view of both the upside and the concerns investors are weighing, start by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Integra LifeSciences Holdings?

If Integra LifeSciences Holdings has your attention, it is worth widening your watchlist so you can compare different risk, income, and valuation profiles side by side.

• Target reliable income streams by reviewing companies in the 9 dividend fortresses and see which payouts look most consistent with their underlying cash flows.
• Prioritize resilience and capital preservation by scanning the 79 resilient stocks with low risk scores and focus on businesses with steadier historical risk scores.
• Hunt for potential future standouts with the screener containing 19 high quality undiscovered gems before they attract wider market attention and become harder to ignore.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.